⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292989 | 0.76 | — | — | |
| SCHEMBL3536369 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL7444276 | 0.72 | EPHX2 (0.46) | — | |
| SCHEMBL232903 | 0.71 | — | — | |
| SCHEMBL27621107 | 0.71 | — | — | |
| SCHEMBL2306049 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL1902782 | 0.71 | EPHX2 (0.48) | — | |
| SCHEMBL10126252 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL1908195 | 0.71 | — | — | |
| SCHEMBL4598964 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4801703-A | PHOSPHORUS COMPOUNDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-01-31 | — | — | US | claimed |
| US-11865195-B2 | Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20200390912-A1 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| EP-2775906-B1 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING | UNIV YALE (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20180177901-A1 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20150023873-A1 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| EP-1622647-B1 | VITRONECTIN RECEPTOR ANTAGONIST COMPOUNDS AND THEIR USE IN THE PREPARATION OF RADIOPHARMACEUTICALS | LANTHEUS MEDICAL IMAGING INC (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-1307226-B1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | LANTHEUS MEDICAL IMAGING INC (US) | 2008-11-19 | — | — | EP | disclosed |
| US-7332149-B1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-02-19 | — | — | US | disclosed |
| US-7321045-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| WO-2001060416-A2 | MATRIX METALLOPROTEINASE INHIBITORS AS TARGETING COMPONENTS IN DIAGNOSTIC AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-08-23 | — | — | WO | disclosed |
| EP-1068224-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | Du Pont Pharmaceuticals Company (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-1068222-A1 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION AND FOR IMAGING AND TREATMENT OF CANCER | Du Pont Pharmaceuticals Company (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-2000035492-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035488-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035887-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARM CO (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999058162-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-11-18 | — | — | WO | disclosed |
| WO-1999051628-A1 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION AND FOR IMAGING AND TREATMENT OF CANCER | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-10-14 | — | — | WO | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |